Detection of genetic alterations in pancreatic cancers by comparative genomic hybridization coupled with tissue microdissection and degenerate oligonucleotide primed polymerase chain reaction - PubMed (original) (raw)
Comparative Study
doi: 10.1159/000059573.
Affiliations
- PMID: 12065873
- DOI: 10.1159/000059573
Comparative Study
Detection of genetic alterations in pancreatic cancers by comparative genomic hybridization coupled with tissue microdissection and degenerate oligonucleotide primed polymerase chain reaction
Tomohiko Harada et al. Oncology. 2002.
Abstract
The aim of this study was to elucidate cytogenetic changes in pancreatic cancers (PCs) and to examine their clinical implications. We screened for genetic alterations in 32 primary PCs including 4 cases with distant organ metastasis using comparative genomic hybridization coupled with tissue microdissection and degenerate oligonucleotide primed polymerase chain reaction (DOP-PCR). The present study revealed frequent gains of chromosomes 13q and 15q and a loss of Xq in addition to a high prevalence of chromosomal imbalances. The average number of total genetic alterations and gains tended to be higher in N1 tumors (TNM classification) than in N0 tumors. The average number of amplifications was significantly higher in M1 tumors than in M0 tumors (p = 0.024). Gain/amplification of 20q was more frequently observed in M1 tumors than in M0 tumors (p = 0.016), and this change was also detected in all of 4 distant metastatic lesions. Losses of 6q, 8p, 9p, 17p, and 18q were recurrent in N0 and M0 tumors, and these alterations were also retained in N1 and M1 tumors. These observations suggest that these genetic losses contribute to the development of PCs and that increases in the DNA copy number confer an aggressive character on cancer cells. Especially, gain/amplification of 20q was associated with the potential of distant organ metastasis of tumor cells.
Copyright 2002 S. Karger AG, Basel
Similar articles
- Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays.
Harada T, Chelala C, Bhakta V, Chaplin T, Caulee K, Baril P, Young BD, Lemoine NR. Harada T, et al. Oncogene. 2008 Mar 20;27(13):1951-60. doi: 10.1038/sj.onc.1210832. Epub 2007 Oct 22. Oncogene. 2008. PMID: 17952125 Free PMC article. - Molecular cytogenetic characterization of pancreas cancer cell lines reveals high complexity chromosomal alterations.
Griffin CA, Morsberger L, Hawkins AL, Haddadin M, Patel A, Ried T, Schrock E, Perlman EJ, Jaffee E. Griffin CA, et al. Cytogenet Genome Res. 2007;118(2-4):148-56. doi: 10.1159/000108295. Cytogenet Genome Res. 2007. PMID: 18000365 Review. - CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases.
Brisset S, Schleiermacher G, Peter M, Mairal A, Oberlin O, Delattre O, Aurias A. Brisset S, et al. Cancer Genet Cytogenet. 2001 Oct 1;130(1):57-61. doi: 10.1016/s0165-4608(01)00454-x. Cancer Genet Cytogenet. 2001. PMID: 11672775 Review.
Cited by
- Identification of genetic alterations in pancreatic cancer by the combined use of tissue microdissection and array-based comparative genomic hybridisation.
Harada T, Baril P, Gangeswaran R, Kelly G, Chelala C, Bhakta V, Caulee K, Mahon PC, Lemoine NR. Harada T, et al. Br J Cancer. 2007 Jan 29;96(2):373-82. doi: 10.1038/sj.bjc.6603563. Br J Cancer. 2007. PMID: 17242705 Free PMC article. - Whole genome amplification of DNA from laser capture-microdissected tissue for high-throughput single nucleotide polymorphism and short tandem repeat genotyping.
Rook MS, Delach SM, Deyneko G, Worlock A, Wolfe JL. Rook MS, et al. Am J Pathol. 2004 Jan;164(1):23-33. doi: 10.1016/S0002-9440(10)63092-1. Am J Pathol. 2004. PMID: 14695315 Free PMC article. - The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.
Samuel N, Hudson TJ. Samuel N, et al. Nat Rev Gastroenterol Hepatol. 2011 Dec 20;9(2):77-87. doi: 10.1038/nrgastro.2011.215. Nat Rev Gastroenterol Hepatol. 2011. PMID: 22183185 Review. - Multiple genes identified as targets for 20q13.12-13.33 gain contributing to unfavorable clinical outcomes in patients with hepatocellular carcinoma.
Wang D, Zhu ZZ, Jiang H, Zhu J, Cong WM, Wen BJ, He SQ, Liu SF. Wang D, et al. Hepatol Int. 2015 Jul;9(3):438-46. doi: 10.1007/s12072-015-9642-0. Epub 2015 Jun 12. Hepatol Int. 2015. PMID: 26067772 - Prognostic value of metastin expression in human pancreatic cancer.
Nagai K, Doi R, Katagiri F, Ito T, Kida A, Koizumi M, Masui T, Kawaguchi Y, Tomita K, Oishi S, Fujii N, Uemoto S. Nagai K, et al. J Exp Clin Cancer Res. 2009 Jan 21;28(1):9. doi: 10.1186/1756-9966-28-9. J Exp Clin Cancer Res. 2009. PMID: 19154616 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical